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1. Introduction
Genes for a given trait are passed down to progeny from 
both parents in accordance with Mendelian inheritance. 
However, these genes are epigenetically marked before 
transmission, which alters their levels of expression. Such a 
phenomemon, called genomic imprinting, takes place before 
gamete formation and is erased during the formation of germ 
line cells. Genomic imprinting is an epigenetic phenomenon. 
Epigenetics entail the inducible genetic changes in an 
organism in which both adaptiveness and specifi city may be 
very high. Epigenetic changes signify those changes in the 
gene expression of organisms which are global in nature and 
can be induced through a common or more universal system. 
The most common mechanisms that produce epigenetic 
changes are DNA methylation and histone acetylation.
Viruses have co-evolved with their hosts, which has 
given them the unique ability to adjust and exploit the 
host system for their propagation. They have evolved 
distinctive strategies to repress host immune response genes 
through epigenetic regulation of immune gene clusters. In 
the following sections are described various epigenetic 
apparatus that are normally present in the host, and how 
they can be manipulated by pathogenic organisms for 
their propagation. This review is an attempt to provide 
a holistic and comparative view of a relatively nascent 
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area of research and to clarify the ambiguities associated 
with pathogenic immune evasion mechanisms related to 
epigenetic alterations.
2. Role of epigenetics in regulation of gene expression
Epigenetic control of gene expression is complex and 
consists of multiple facets, including histone modifi cation, 
miRNA pathways and DNA methylation. Histone 
acetylation and DNA methylation are the main mechanisms 
of epigenetic regulation (Zocchi and Sassone-Corsi 2010). 
The miRNA pathway is usually activated during cancer or 
viral infection. A detailed description of the role of miRNA 
in gene regulation has been provided in a later section.
2.1 Histone modifi cations
The extent of acetylation of core histones refl ects a balance 
between the opposing activities of histone acetyltransferases 
(HATs) and histone deacetylases (HDACs) (fi gure 1). In 
the deacetylated state, histones package the DNA into 
condensed chromatin, termed nucleosomes, which, in turn, 
prevent access of transcriptional activators to their target 
sites, thus resulting in transcriptional repression. Relaxation 
of the nucleosomes occur by the acetylation of the conserved 
N-terminal histone tails, which decrease the interaction of 
the positively charged histone tails with the negatively 
charged phosphate backbone of DNA. The nucleosomal 
relaxation facilitates access of transcriptional activators and 
allows gene expression. Furthermore, many transcriptional 
co-activators such as p300 and CBP (CRE-binding protein, 
where CRE is cAMP-response-element-binding protein) 
display intrinsic HAT activity, which reinforces chromatin 
relaxation.
Hypoacetylated histones are associated with 
transcriptionally silent genes, which is consistent with the 
discovery that HDACs are present in the same complex along 
with other transcriptional repressors. There are four groups 
of HDAC proteins classifi ed according to function and DNA 
sequence similarity. The fi rst two groups are considered to 
be Zn2+-dependent “classical” HDACs whose activities are 
inhibited by Trichostatin A (TSA), whereas the third group 
is a family of NAD+-dependent proteins not affected by 
TSA. The fourth group is considered an atypical category 
of its own, based solely on DNA sequence similarity with 
the others. Class I HDACs (HDACs 1, 2, 3 and 8) are 
localized in the nucleus and are present as multi-protein 
complexes. They are not DNA-binding proteins. HDACs 
located in the nucleus show maximum deacetylase activity. 
They have ubiquitous expression and play key roles in 
normal cells. Class II HDAC (HDACs 4, 5, 7, 9, 6 and 10) 
expression is tissue-specifi c and can shuttle between the 
nucleus and cytoplasm (de Ruijter et al. 2003). This class 
of HDACs has lower deacetylase activity than their class I 
counterparts. The functions of class I and class II HDACs 
in epigenetic regulation of gene expression have been 
well-elucidated. Class IIb HDACs (HDAC6 and HDAC10) 
contain two deacetylase domains and are capable of 
deacetylating cytoplasmic proteins to modulate their activity 
(Duong et al. 2008). Class III HDACs (the sirtuins) show 
anti-oxidant properties, while functionally there is much to 
be studied as far as class IV HDACs (potentially, HDAC11) 
are concerned (Wang et al. 2009).
Figure 1. Epigenetic regulation of gene expression: (a) Inhibition: HDACs deacetylate histone tails, which clamp onto genome around 
nucleosome, thus inhibiting transcription. Methyl-binding proteins (e.g. MBDs) bind to methylated CpG islands in the promoter site of 
DNA and form an inhibitory complex with HDACs and other co-inhibitory molecules (not shown) to further strengthen inhibition. (b) 
Activation: histone acetylases such as CBP acetylate histone tails to unclamp DNA and allow unwinding. CBP also acts as a co-activator 
along with CREB, which bind to promoter sequences to initiate transcription.
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2.2 DNA methylation
Methylation at CpG dinucleotides in genomic DNA 
is another fundamental epigenetic mechanism of gene 
expression control in vertebrates. Proteins with a methyl-
CpG-binding domain (MBDs) can bind to single methylated 
CpGs and most of them are involved in transcriptional 
control (Bird 1996; Roloff et al. 2003). So far, fi ve 
vertebrate MBDs have been described as MBD family 
members: MBD1, MBD2, MBD3, MBD4 and MeCP2 
(Ballestar and Wolffe 2001; Wade 2001). Strong evidence 
exists for the correlation between DNA hypermethylation, 
hypoacetylation of histones, tightly packed chromatin and 
transcriptional repression. Except for MBD4, all other 
members of the MBD family are associated with HDACs, 
and a transcriptional repression mechanism mediated by the 
recruitment of HDACs has been shown for MeCP2, MBD1 
and MBD2 (Ohki et al. 1999).
3. Aspects of non-epigenetic viral immune evasion: 
prominence of mimicry
Viruses can exist in two forms: as extracellular virion particles 
or as intracellular genomes. While the former is resistant to 
physical stress, the latter is more susceptible to the humoral 
immune control. Various mechanisms of immune evasion are 
devised to protect viral genome and enhance their replication 
capabilities. Viral immunoregulatory proteins may be 
encoded as genes either with or without sequence homology 
with host genes. Large DNA viruses such as herpesvirus 
encode viral homologs derived from mutated host genes. 
On the other hand, certain viral immunoregulatory genes do 
not bear a sequence similarity to host genes, and may refl ect 
a model of viral co-evolution with host through selection 
pressure (Alcami and Koszinowski 2000).
At the antigen presentation level, major histocompatibility 
complex (MHC) gene products are important factors 
in intercellular recognition and self- and non-self-
discrimination. The various host-mimicking proteins of 
the virus interfere with antigen-binding properties of MHC 
molecules. Epstein–Barr virus EBNA1 protein is capable of 
blocking antigen-processing while the herpes simplex virus 
ICP47 protein hinders transporters associated with antigen 
processing (TAP) activity. Viruses can modify maturation, 
assembly and export of MHC class I molecules. They are 
able to downregulate MHC class I molecules while hindering 
MHC class II functions (Farrell and Davis-Poynter 1998).
At the level of anti-viral responses, viruses are able to 
block interferon (IFN)-induced transcriptional responses 
and JAK/STAT signalling pathways. Critical members of 
the IFN effecter pathway such as the dsRNA-dependant 
protein kinase (PKR) can be inhibited by vaccinia virus 
(Smith et al. 1997). Eukaryotic translation initiation factor 
2α (eIF-2α) and RNase L system can be inhibited by the 
herpes simplex virus and the vaccinia virus respectively 
(Goodbourn et al. 2000). Poxviruses encode soluble 
homologs of IFN-α, IFN-β and IFN-γ receptors capable of 
binding to host interferons and inactivating them. Synthesis 
of interferons can also be blocked by several viruses 
(Spriggs 1996).
The African swine fever virus (ASFV) replicates in 
macrophages and encodes an IκB homolog that blocks 
nuclear factor NFκB and nuclear-factor-activated T-cell 
(NFAT) mediated cytokine expression (Miskin et al. 1998). 
Certain viruses encode ligands for the tumour necrosis factor 
(TNF) family of receptors. Epstein–Barr virus (EBV) latent 
membrane protein 1 (LMP1) recruits components of the TNF 
receptor (TNFR) and CD40 to activate selective cytokine 
responses that could be benefi cial for the virus, such as 
enhancing cell proliferation (Farrell 1998). Occupying the 
ranks of cytokine/chemokine modulation are the production 
of “virokines” and “viroreceptors”, the viral homologs of 
cytokines and cytokine receptors. While virokines induce 
signalling pathways promoting virus replication, the 
viroreceptors neutralize host cytokine activity (Lalani et 
al. 2000; Tortorella et al. 2000). The persistent prevalence 
of undetectable Japanese encephalitis virus (JEV) inside 
peripheral macrophages and the signifi cant absence of 
cell death while in the blood stream is a major cause of 
concern in detecting JEV infection. Studies have shown that 
cytokine/chemokine modulation is an important mediator of 
immune evasion by this virus. Monocyte chemotactic protein 
1 (MCP1) and interleukin 6 (IL6) are down-regulated, 
causing inability to recruit mononuclear leukocytes and 
other components of the peripheral immune system, and 
interleukin 10 (IL10), an anti-infl ammatory cytokine, is up-
regulated, thus inhibiting macrophage activation and antigen 
presentation (Dutta et al. 2010).
Apoptosis, a mechanism of controlled cell death can 
act as an early innate immune response against cellular 
perturbations by viral infection. However, viruses have 
devised ways to inhibit apoptosis. The immune evasion 
strategies at the apoptotic level include inhibition of 
caspases, up-regulation of the anti-apoptotic bcl2, blocking 
of TNF receptors and inactivation of pro-apoptotic IFN-
induced PKR and the tumour suppressor p53 (Alcami and 
Koszinowski 2000; Everett and McFadden 1999).
4. Aspects of epigenetic viral immune evasion: cycle of 
acetylations and methylations
Emerging evidence indicates that programmed DNA 
rearrangements, imprinting phenomenon, germ line 
silencing, developmentally cued stem cell division, and 
overall chromosomal stability and identity are all infl uenced 
by epigenetic alterations of the underlying chromatin 
structure (Jenuwein and Allis 2001). Retroviruses and 
several DNA viruses are capable of integrating their genome 
into the host genome. The host, unable to differentiate 
self from non-self, helps the packaging of the viral DNA 
into nucleosomes or nucleosome-like structures involving 
histones (Oh and Fraser 2008; Dahl et al. 2007; Imai et al. 
2010). Once inside the host genome, viral gene expression 
can be regulated just like its host. The virus can stay latent 
by silencing its gene or can robustly proliferate by activating 
it. Viral DNA uses not only host transcription factors but 
also epigenetic regulators. The effects of viral epigenetic 
control of gene expression also extends to regulating host 
gene expression, often by silencing host immune response 
genes present in chromosomal clusters (Wong et al. 1999). 
Transcriptional silencing by methylation of DNA and 
chromatin remodeling by HDACs leading to inhibition 
of DNA-binding of some transcription factors has been 
shown to have a vital role in suppression of the host’s innate 
immune response to infection, especially viral infection. 
The following are some currently known viruses that exhibit 
unique epigenetic immune evasion mechanisms to survive 
and propagate in their host.
4.1 Viral CpG island methylation paradigm
Several DNA viruses and retroviruses integrate their genome 
into the host genome, resulting in the formation of a latent 
provirus capable of shutting down its transcription at will. 
Thus, while virus titer may intermittently fall and make their 
detection diffi cult, a reactivation of provirus will give rise to 
increasing viral load and infection. The inactivation of virus 
genome occurs via methylation of the viral promoter CpG 
island and recruitment of associated inhibitory complexes 
(fi gure 2). The following are some viruses that are able to 
elude an immune response in the above manner.
4.1.1 Human immunodefi ciency virus (HIV): In the case 
of HIV-1, CD4+ T-cells are the reservoirs of latent virus 
particles (Kauder et al. 2009). The existing hypothesis for 
the latent infection of CD4+ T-cells is that the virus infects 
T-cells just prior to their natural switch to a quiescent state or 
naïve T-cells undergoing differentiation during thymopoiesis 
(Pearson et al. 2008; Margolis 2010). The HIV viral 
activator Tat is a very potent activator of gene expression 
and interacts with HATs and HDACs to derepress inhibition 
of transcription, while the HIV promoter is very responsive 
to cellular activators of transcription such as TNFα and 
NFκB (Romani et al. 2010). Thus, transcriptional regulatory 
mechanisms are required to allow HIV to establish and 
maintain a persistent latent infection, and studies have 
shown the importance of histone-modifying and DNA-
methylating enzymes in this respect (Archin and Margolis 
2006). Such latent infection renders highly active anti-
retroviral therapy (HAART) ineffective. Experiments have 
revealed that two CpG islands fl ank the HIV-1 transcription 
start site, and a methyl CpG domain protein 2 (MBD2) has 
been identifi ed as a regulator of HIV-1 latency. During 
latency, a MBD2 and HDAC2 complex has been found 
at one of these CpG islands. Studies with small molecule 
inhibitor of methylation, 5 -aza-2 deoxycytidine (aza-CdR), 
have confi rmed that cytosine methylation and MBD2 are 
epigenetic regulators of HIV-1 latency. NFκB signalling 
is responsible for HIV-1 reactivation, but a signifi cant 
proportion of the latent HIV-1 remains silent even when 
NFκB is activated. In the latent state, HDAC1 is recruited 
to the HIV-1 promoter by several sequence specifi c factors 
including NFκB p50 and CBF-1 (CSL family protein). 
MBD2, which is also recruited to the HIV-1 promoter site 
via a hypermethylated CpG island, silences transcription by 
recruitment of HDAC2 and the nucleosome remodeling and 
deacetylase (NuRD) complex. TNFα, an activator of latent 
HIV-1, on its own, can reactivate only a small percentage of 
the cell population, ranging from 16% to 41%. Aza-CdR, an 
inhibitor of methylation, could reactivate latent HIV-1, but 
on its own showed little effect. In contrast, dual treatment 
with both TNFα (activator of NFκB) and aza-CdR induced a 
dramatic increase in HIV-1 gene transcription.
In addition to the above mechanisms involving MBDs 
and HDACs, trimethylation of the ninth lysine of histone 
3 (H3K9) by a histone methyltransferase (HMT) Suv39H1 
is also responsible for HIV-1 gene silencing and latency 
(Lachner et al. 2003; Jenuwein 2006; Lee, Teyssier et al. 
2005). Further experiments have shown the involvement of 
another HMT, G9a, which has a greater infl uence on histone 
methylation than Suv39H1 (Tachibana et al. 2001). It was 
shown that G9a knock-down was associated with loss of 
Suv39H function (Gazzar et al. 2008). This data suggested a 
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Figure 2. The methylation paradigm in the HIV system: (a) Latent virus: The HIV gene integrates into the host genome. Its transcription 
start site has CpG islands that are methylated by DNMTs, and bound by methyl-binding proteins such as MBD2. A inhibitory complex forms 
containing HDACs and other co-inhibitors like NuRD. This gives rise to latent provirus. (b) Virulent virus: In the presence of stimulation, such 
as TNFα, the complexes inducing latency such as HDAC and MBD2 are removed from the viral promoter region. Tat interacts with HDACs 
to remove them from the inhibitory complex. It also interacts with CBP/p300 and activates  RNA polymerase complex to initiate transcription 
from provirus template. (c) Combinational therapy for AIDS—a major setback in anti-retroviral therapy: By administering a HDACi such as 
valproic acid and a DNMTi such as 5 -azacytidine, in combination with HAART, an effective treatment for AIDS can be deviced. While the 
HDACi and DNMTi derepress provirus transcription, HAART detects and inhibits viral replication and propagation in host.
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downstream location of Suv39H1 in relation to G9a. Thus, 
the proposed mechanism of HIV-provirus silencing entailed 
initial recruitment of G9a followed by dimethylation 
of histone H3 (H3K9me2), which could be recognized 
by a heterochromatin protein complex containing a 
heretochromatin protein (HP1) and HDACs (Rea et al. 2000; 
Ogawa et al. 2002; Roopra et al. 2004; Sampath et al. 2007; 
Gazzar et al. 2008), followed by recruitment of Suv39H1, 
thus converting a silent euchromatin into a heterochromatin. 
The role of G9a may thus be very signifi cant in the 
establishment of latency of HIV-1 (Imai et al. 2010).
4.1.2 Bovine leukemia virus (BLV): BLV is a retrovirus 
closely related to the human T-cell leukemia virus type 
1 (HTLV1), a tumorogenic virus affecting humans. It is 
responsible for causing infectious mononucleosis and B-cell 
leukemia in cattle. Similar to the human immunodefi ciency 
virus, the BLV evades immunity through genomic 
integration and viral latency (Merimi et al. 2007). Studies 
using TSA (an HDAC inhibitor) and 5 azacytidine (a DNA 
methyltransferases [DNMT] inhibitor) have revealed a 
mechanism of viral gene expression involving chromatin 
remodeling. Silencing of viral gene expression has been 
proposed as a mechanism that leads to immune evasion. BLV 
provirus, during latency, does not seem to integrate at specifi c 
sites of the host genome. BLV retroviral transactivator Tax 
has been shown to be functionally homologous to the 
HIV1 Tat protein in having a relaxing impact on epigenetic 
silencers of integrated provirus. Transcriptional regulation 
at the HTLV1 promoter sequence is mediated through the 
binding of Tax with HDACs (Ego et al. 2002; Agbottah
et al. 2006; Lemasson et al. 2006; Van Lint 2000). In HTLV1 
infection, HDAC1 directly interacts with Tax, increasing 
levels of acetylated histones H3 and H4 in the vicinity of the 
HTLV1 LTR (Lu et al. 2004).
Activation of Tax in BLV by treatment with HDAC and 
DNMT inhibitors causes derepression of silenced genes in 
tumour cells. Whether or not it may help in limiting tumour 
progression remains to be seen. Progress in clinical treatment 
is possible especially in combination with chemotherapeutic 
drugs.
4.1.3 Epstein–Barr virus (EBV): EBV infects the host and 
establishes long-term latency in B-lymphocytes. EBV 
alternates between latency and the lytic replication, and 
during latency, the viral genome is largely silenced by the 
host-driven methylation of CpG islands. Infection of EBV is 
common throughout the human population, and EBV is the 
causative agent of infectious mononucleosis and is linked 
to malignancies such as endemic Burkitt Lymphoma (BL), 
nasopharyngeal carcinoma (NPC) and Hodgkin disease 
(HD) (Karlsson et al. 2008). In BL cells, the EBV genome is 
heavily methylated and very few viral genes are expressed, 
and this is mediated in part by methyl-CpG-binding proteins 
with methylated DNA, leading to transcriptional silencing 
and chromatin remodeling. EBV nuclear antigen 3C 
(EBNA3C) has been shown to repress EBV Cp latency-
associated promoter elements, and in vitro studies have 
shown that it forms a complex with HDAC1 to repress the 
transcription from the Cp promoter (Radkov et al. 1999).
4.2 Host CpG island methylation paradigm
There are other viruses which modulate immune responses 
by suppressing expression of certain immune response genes 
and cytokines. Some cancer-causing viruses may suppress 
apoptotic proteins (fi gure 3), while others may inhibit anti-
viral proteins. The above are achieved by the interaction of 
viral proteins with epigenetic modulators of gene expression 
especially methyltransferases, which are responsible for 
methylating host promoter CpG islands.
4.2.1 Hepatitis B virus (HBV): HBV, of the Hepadnaviridae 
family causes hepatocellular carcinoma in humans. The 
hepatitis B virus X protein (HBx) plays an important role 
in HBV-mediated hepatocarcinogenesis (Block et al. 2003; 
Kim et al. 2010). HBx can affect transcription of several 
genes involved in transformation, cell cycle regulation, 
apoptosis and cell adhesion through its association with 
transcriptional activators (Haviv et al. 1998). HBx also 
interacts with and activates several signalling molecules that 
lead to transcriptional up-regulation of a number of cellular 
genes, especially those of growth factors and oncogenes 
(Benn and Schneider 1994). HBx can epigenetically
regulate inactivation of tumour suppressor protein 
retinoblastoma (Rb) via the down-regulation of a cellular 
senescence protein p16INK4a, and by this mechanism 
overcomes stress-induced premature senescence (SIPS). 
p16INK4a is a major determinant of senescence for 
lymphocytes, macrophages and astrocytes, and its repression 
is a chief cause of HBV-induced immune evasion and cancer 
(Kim et al. 2010).
Methylation anomalies play a fundamental role in 
tumorigenesis and immune evasion. A strong correlation 
exists between HBV infection and epigenetic alterations 
of tumour suppressor genes including p16INK4a (Shim et 
al. 2003). HBx has been shown to activate expression 
of DNMT1, which methylates p16INK4a (Lee et al. 2005). 
Apparently, DNMT1 is also up-regulated in response to 
the CpG islands of HBV DNA as a possible innate immune 
response to infection (Liu et al. 2009) and, contradictory 
to its purpose, acts instead in enhancing HBV-mediated 
hepatocarcinogenesis.
4.2.2 Human papillomavirus (HPV): HPV produces 
infection in the stratifi ed epithelium of the skin or mucous 
membrane. HPV is a cause of nearly all cases of cervical 
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cancer (Walboomers et al. 1999), and is another virus that 
shows innate immune evasion strategies. Type-1 interferon 
signal transduction has been shown to be a likely target of 
viral oncoproteins E6 and E7 of high-risk HPV. HPV18 E6 
prevents JAK-STAT1/2 tyrosine phosphorylation (Li et al. 
1999). Studies on HPV16 E6 encoding cells have suggested 
that IFN-κ expression is suppressed by de novo methylation 
within a CpG-rich area near the transcriptional start site, 
IFN-κ being the only keratinocyte-specifi c IFN involved in 
innate immunity. Inhibition of this pathway may represent 
an early and central event in the development of cervical 
cancer (Rosl et al. 1993; Rincon-Orozco et al. 2009). E6 
has wider functions related to the ubiquitin-proteosome 
system. It binds to the host protein E6-AP, a member of 
the HECT (homologous to the E6-AP carboxyl terminus) 
domain E3 ligase protein family and possibly other ubiquitin 
ligases. E6-AP ubiquitinates p53 and PDZ family proteins 
including hDIg, hScribble and hMAGI, designating them 
to proteosomal degradation (Lin et al. 2009; Werness et 
al. 1990). This reduces the level of these key cell cycle 
regulators without their mutation.
Genetic evidence has suggested that HDAC1 and 
HDAC2 interact with E7 and that these interactions are 
critical for E7-mediated transformation (Lin et al. 2009). 
E7 binds to pRb, HDAC1 and HDAC2 (Dyson et al. 1989). 
It diminishes the tumour suppressor retinoblastoma protein 
(pRb) levels through proteosomal degradation (Huh et al. 
2007). HDAC1 and HDAC2 may not directly interact with 
E7. They bind to E7 through the interaction of the Mi2β 
protein, a component of the mammalian NuRD chromatin 
remodeling complex (Brehm et al. 1999; Lin et al. 2009) and 
bring about gene suppression.
4.3 Host–viral acetylation–deacetylation paradigm
Viral proteins are multifunctional, and several viruses express 
proteins that have been shown to interact with HATs and 
HDACs, not only to modulate host immunity but also to 
enhance viral gene expression (fi gure 4). The following are very 
interesting examples of viral–host protein–protein interactions 
bringing about immune evasion and viral pathogenesis.
4.3.1 Simian virus 40 (SV40): SV40 is a polyomavirus, 
with DNA as genetic material, and having the potential to 
Figure 3. Host CpG island methylation in HBV infection: During HBV infection, the HBx antigenic protein up-regulates DNA 
methyltransferases (DNMT1) expression. P16INK4a, a senescence factor is down-regulated, which subsequently down-regulates Rb, a 
tumour supressor.
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cause tumours in their hosts (monkeys or humans) (Valls et 
al. 2007). The SV40 large T-antigen (T Ag) is a 708-amino-
acid multifunctional oncoviral protein involved in numerous 
viral and cellular processes, including viral replication, 
transcriptional activation and repression, and blockade of 
differentiation and cell transformation (Moran 1993). T Ag 
can be acetylated by CBP in a p53-dependent manner (Poulin 
et al. 2004). The T Ag along with other viral oncoproteins 
undergo complex interactions with various intracellular cell 
control proteins (Ali and Decaprio 2001) and transcriptional 
regulators such as p53 (Levine 1990; Sheppard et al. 1999), 
pRb and Rb-related proteins p107 and p130 (Decaprio et al. 
1988; Ludlow et al. 1990; Cobrinik et al. 1992) and CBP/
p300 (Yaciuk et al. 1991; Eckner et al. 1996; Avantaggiati et 
al. 1996). The CBP/p300 is a coactivator protein involved in 
both proliferative and differentiation pathways, and contains 
HAT activity. CBP/p300 is ubiquitously expressed and 
regulates a broad spectrum of biological activities such as 
proliferation, differentiation, cell cycle control and apoptosis. 
SV40 oncoproteins select HAT enzymes as cellular partners, 
in some cases disrupting enzymatic activity. The E1A antigen 
can increase, decrease or redirect CBP/p300 HAT activity 
(Hamamori et al. 1999; Ait-Si-Ali et al. 1998; Chakravarti 
et al. 1999), while T Ag interacts with CBP to increase its 
HAT activity (Valls et al. 2003). CBP/p300 can acetylate 
several viral oncoproteins such as E1A (Zhang et al. 2000) 
and T Ag (Poulin et al. 2004). However, by interacting with 
CBP/p300, T Ag affects the transcriptional levels of the 
cAMP-responsive promoter. T Ag down-regulates CBP/
p300-mediated transcriptional activity (Eckner et al. 1996; 
Avantaggiati et al. 1996). This repression is accompanied by 
histone H3 deacetylation and is TSA-sensitive. Along with 
the T Ag, HDAC1 counteracts CBP transactivation function. 
HDAC1 is also responsible for the repression of thymidine 
kinase (TK) and platelet-derived growth factor (PDGF) β-
receptor promoters by chromatin deacetylation. Thus, it can 
be seen that the T Ag can interact with both HAT (Avantaggiati 
et al. 1996; Eckner et al. 1996; Valls et al. 2003) and HDAC 
activities (Valls et al. 2007). This characteristic of the T Ag to 
show a dual nature may actually be benefi cial in stimulating 
growth and bringing about effi cient and rapid changes, by 
activating one set of genes while repressing another. This 
enables the virus to not only repress the host innate immunity 
by global inhibition of immune response genes by HDAC1 
but also to activate several viral genes by acetylation of viral 
proteins by HAT activity of CBP/p300.
Figure 4. Host–viral acetylation–deacetylation on HSV infection: HSV genome associates with histone proteins, and CBP/p300
histone acetyltransferases activity is essential to promote transcription. Moreover, HSV gene products Ser/Thr Us3 kinases are capable 
of inhibiting HDAC suppressor activity by phosphorylating them. This not only enhances expression but also ensures more potent 
pathogenesis.
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4.3.2 Herpes simplex virus (HSV): HSV is a major cause 
of sexually transmitted disease in the world today. It belongs 
to the family Herpesviridae and is a double-stranded DNA 
virus that undergoes its replication cycle in the nucleus of 
infected cells. Upon fusion of viral and host membranes 
the linear genome in the nucleocapsid is injected into the 
cytoplasm. Along with the genetic material are released 
preformed tegument proteins that have important functions 
in interfering with the host defences and stimulating viral 
gene expression. Studies have shown that the HSV genome 
on entering the nucleus of its host associates itself with 
host histone H3 or modifi ed H3 (Herrera and Triezenberg 
2004; Huang et al. 2006; Kent et al. 2004). However, after 
replication initiates, histones do not appear to be associated 
with newly replicated viral DNA (Oh and Fraser 2008). 
During lytic infection, p300 and CBP HATs are recruited to 
the immediate early gene promoters (Herrera and Triezenberg 
2004). Studies to show HAT activity using curcumin as a 
HAT inhibitor have illustrated the association of chromatin 
remodeling factors with HSV-1 genome transcription 
(Kutluay et al. 2008). Histone deacetylases also have a 
role to play in the regulation of HSV-1 gene expression. 
Various groups have reported that HDACs are involved 
in repression of viral genome through the deacetylation 
of lysine residues on histone tails (Gu et al. 2005; Gu and 
Roizman 2007, 2009; Poon et al. 2006; Poon et al. 2003). 
However, herpesvirus such as HSV-1 has developed various 
mechanisms to block the HDAC repressor activity. HSV-1 
Ser/Thr U
s
3 kinases are capable of indirectly phosphorylating 
HDAC1 and HDAC2 thus rendering them inactive (Pfl um
et al. 2001; Poon et al. 2006). HSV-1 U
s
3 kinases have been 
demonstrated to activate cellular protein kinase A (PKA) 
(Benetti and Roizman 2004). This allows for vigorous gene 
expression and rapid pathogenesis by novel HSV-1 immune 
evasion strategies.
4.3.3 Varicella zoster virus (VCZ): VZV, belonging to 
the family Herpesviridae, infects humans, causes chicken 
pox in children and shingles in adults. It contains a large 
double-stranded DNA genome that replicates in the host cell 
nucleus. Once the viral genome enters the host nucleus, host 
proteins rapidly act to shut down transcription from viral 
DNA, and this consequently blocks or impairs replication 
(Walters et al. 2009). The major host proteins that have 
been shown to have such properties are HDACs, and 
effi cient VZV gene expression, as with other herpesviruses, 
depends on the inhibition of HDACs (Hobbs and DeLuca 
1999; Gwack et al. 2001; Poon et al. 2003; Danaher et al. 
2005). Herpesvirus have evolved a range of mechanisms 
to obstruct the gene-silencing properties of HDACs (Gu et 
al. 2005; Gu and Roizman 2009; Gu and Roizman 2007; 
Poon et al. 2006; Poon et al. 2003). By phosphorylating 
HDACs via HSV-1 Ser/Thr U
s
3 kinases, the HSV-1 virus 
has evolved a successful strategy to evade HDAC repressor 
activities (Poon et al. 2006; Poon et al. 2003). VZV encodes 
ORF66p kinases, orthologs of HSV-1 Ser/Thr U
s
3 kinases 
that are required for the phosphorylation of HDAC1 and 
HDAC2 (Stevenson et al. 1994; Pfl um et al. 2001; Ogg 
et al. 2004; Schaap et al. 2005). Autonomous expression 
of ORF66p has shown marked hyperphosphorylation of 
HDAC1 and HDAC2, and its kinase activity has been shown 
to be responsible for it. ORF66p may not directly transfer 
phosphate groups to HDAC1 and HDAC2, and possibly 
acts via activating a cellular kinase or pathway that, in turn, 
hyperphosphorylates HDAC1 and HDAC2 (Walters et al. 
2009).
4.4 Epigenetic immune control by ssRNA virus
RNA viruses are relatively small and less complicated 
than DNA viruses, and yet they have elaborate epigenetic 
immune evasion strategies, as shown in various studies. 
They are able to regulate host immune gene expression 
by altering methylation and acetylation states of genes 
(fi gure 5). Much needs to be studied to produce some clarity 
in their mechanism. Below are some excerpts from different 
studies going on today regarding this aspect of viral immune 
evasion.
4.4.1 Hepatitis C virus (HCV): HCV is the causative agent 
for hepatitis C in humans. Chronic infection is associated 
with liver fi brosis and cirrhosis. Hepatitis C and hepatitis 
B viruses share similar names because they cause live 
infl ammation in general, but they are distinctly different 
viruses genetically and clinically. The hepatitis C virus is 
a small (+)ssRNA virus of the Flaviviridae family which 
can cause epigenetic modifi cations in its host. The role 
of host miRNA in facilitating HCV replication is already 
well-documented and elaborated later in Section 6 (Jopling 
et al. 2008). Studies on host histone acetylation and DNA 
methylation status on HCV infection is not well studied 
yet. Of the few studies performed, the work of Shuo Li et 
al. seems to stand out in the identifi cation of a regulatory 
T-cell (Treg)-specifi c demethylated region (TSDR), an 
evolutionarily conserved element within the FOXP3 gene 
locus that  is methylated in most T-cells in various degrees, 
except in hepatitis-C-virus-activated Treg cells (Li et al. 
2009). The transcription factor FOXP3 plays an important 
role in the development and function of these cells, and it 
is used as a specifi c marker for their identifi cation. FOXP3 
TSDR demethylation and the consequent expression of 
FOXP3 are very exclusive to activated Treg cells (Baron et 
al. 2007). Treg cells, a specialized subpopulation of T-cells, 
act to suppress activation of immune system in an effort to 
maintain immune system homeostasis and tolerance to self-
antigens. Their activation by HCV can only mean a highly 
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adapted mechanism of viral immune evasion down the 
epigenetic route.
4.4.2 Dengue virus (DNV): Another member of the 
family Flaviviridae, DNV is the causative agent of dengue 
fever (DF) and dengue hemorrhagic fever (DHF), which 
are febrile diseases largely prevalent in the tropics. It has 
been shown that dengue-virus-2-infected endothelial cells 
produce interleukin-8 (IL-8) (Huang et al. 2000). IL-8 is 
a chemokine and a major mediator of the infl ammatory 
response. IL-8 has chemoattractant activity for neutrophils, 
and patients with DF and DHF demonstrated degranulation 
of neutrophils (Juffrie et al. 2000). Transcription of IL-8 
gene can be regulated by the degree of binding of acetylated 
histones (Fusunyan et al. 1999). It is not known whether 
DNV infection in monocytes inhibits HDAC activity. Levels 
of histone acetylation of the IL-8 promoter are very low in 
mock-infected cells, and the status of H3 and H4 acetylation 
seem to refl ect the expression of IL-8 (Timmermann et al. 
2001). Increased IL-8 gene expression is associated with 
increased H3 and H4 acetylation in DNV-infected cells, 
and this can be shown by an increased IL-8 mRNA levels 
and secretion of the chemokine. This is a unique mechanism 
of transcriptional control not previously shown in cytosolic 
RNA viruses (Bosch et al. 2002). Whether this strategy of 
host transcriptional control seen after DNV infection is 
associated with an immune evasion strategy is yet to be 
reported, but it probably plays a role in the pathogenesis 
of plasma leakage seen in dengue hemorrhagic fever and 
dengue shock syndrome (Bosch et al. 2002).
5. Viruses and the miRNA paradigm
MiRNA are short ribonucleic acid (RNA) molecules about 
22 nucleotides long. The human genome encodes more than 
700 miRNAs. RNA stem loops transcribed from introns of 
protein and non-protein-coding genes or even exons are 
cleaved to form miRNAs (Rodriguez et al. 2004).
Viruses can also encode miRNAs. Viral miRNAs serve 
two major functions. They can inhibit the expression 
of cellular factors that play a role in cellular, innate or 
adaptive anti-viral immune responses. Natural killer (NK) 
cell ligand MHC class I chain-related protein B (MICB) 
is down-regulated by miRNAs encoded by EBV, Kaposi’s 
sarcoma-associated herpes virus (KSHV) and human 
cytomegalovirus (HCMV) (Nachmani et al. 2009), while 
EBV encodes miRNA that can inhibit pro-apoptotic protein 
Figure 5. ssRNA virus paradigm of dengue virus: The dengue virus model of epigenetic immune evasion involves an up-regulation of 
acetylated histones H3 and H4. This has been correlated with an increasing expression of interleukin 8 secretion. High levels of IL8 are 
probably responsible for plasma leakage that happens as a result of DHF and dengue shock syndrome..
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PUMA (Choy et al. 2008). Such down-regulation of the 
host gene expression is potentially very helpful to virus 
propagation. Secondly, viral miRNAs can inhibit expression 
of viral proteins, including key viral immediate-early or 
early regulatory proteins. HSV1 down-regulates immediate-
early transactivators ICP0 and ICP4 in latently infected 
cells by viral miRNAs that are expressed at high levels 
during latency, but not during productive viral replication, 
stabilizing the latent state as a result (Umbach et al. 2008). 
Several polyomaviruses down-regulate the expression of the 
viral T antigens and key early transcription factors at late 
stages in the viral replication cycle. In the case of SV40, 
SVmiRNAs accumulate at late times of infection. They are 
perfectly complementary to viral mRNAs and target those 
for cleavage. The expression of viral T antigen is reduced 
without having any effect on the yield of infectious virus 
particles. Studies have shown that wild-type SV40-infected 
cells are less susceptible to lysis by cytotoxic T-cells than 
mutants lacking SVmiRNAs. Wild-type virus particles also 
elicit less cytokine production by such cells (Sullivan et al. 
2005). There is, of course, not enough evidence to support 
the role of miRNA in replication and pathogenesis of viruses. 
Table 1 Summary of the epigenetic viral immune evasion strategies
Virus Viral strategy* Host epigenetic agents 
targeted*
Immune evasion
1. Viral CpG island methylation paradigm
HIV Family: Retroviridae Induction of latency by viral 
genome integration.
Histone H3, HDAC1, 
HDAC2, MBD2, HMTs, 
NFκB, Suv39H1, G9a.
Transient absence of viral gene 
products due to DNA methylation, 
histone deacetylation and histone 
methylation.
BLV Family: Retroviridae Viral latency, viral Tax protein 
acts as activator.
Histones, HDACs. Transient absence of viral gene 
products due to DNA methylation 
and histone deacetylation.
EBV Family: Herpes-viridae Viral latency and gene silencing 
by viral protein EBNA3C.
Methylation of CpG 
islands, methyl binding 
proteins, HDAC1.
Transient absence of viral gene 
products due to DNA methylation 
and histone deacetylation.
2. Host CpG island methylation paradigm
HBV Family: Hepadna-viridae Host genome methylation via 
HBx protein
DNMT1, p16INK4a, E-
cadherin, Rb.
Inhibition of senescence and 
apoptotic proteins.
HPV Family: Papilloma-viridae E6 and E7 oncoproteins 
suppress IFN-κ by methylation 
of CpG island.
CpG island of IFN-κ 
promoter, HDAC1, 
HDAC2, JAK-STAT1/2.
Inhibition of Type1 IFN signal 
transduction.
3. Host viral acetylation-deacetylation paradigm
SV40 Family: Polyoma-Viridae Actions of large T antigen and 
E1A to inhibit immune response 
genes, while activating viral 
transcription and replication.
CBP/p300, HDAC1, TK, 
PDGF β-receptor.
Dual action inhibiting innate 
immunity, while enhancing viral 
gene expression.
HSV Family: Herpes-viridae Suppression of HDAC repressor 
activity on viral genome by 
Ser/Thr U
s
3 kinases.
Histone H3, CBP/p300, 
HDAC1, HDAC2.
Obstruction of HDAC inhibition of 
viral genome.
VZV Family: Herpes-viridae Suppression of HDAC repressor 
activity on viral genome by 
ORF66p kinases.
HDAC1, HDAC2. Obstruction of HDAC inhibition of 
viral genome.
4. Epigenetic immune control by ssRNA virus
HCV Family: Flaviviridae Host gene demethylation Treg cell FOXP3+ TSDR. Activation of Treg cells, modulators 
of immune system.
DNV Family: Flaviviridae Induction of increased 
acetylation of histones.
Histones H3 and H4, Il-8. Increased IL-8 production playing 
important role in pathogenesis 
(possible immune evasion strategy 
linked)
* The list may not be exhaustive – factors having sound evidence in favour of them have only been included.
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In fact, the mutant polyomavirus lacking its only miRNA 
replicated indistinguishably from wild-type in infected cells 
(Sullivan et al. 2009).
Alternatively, viruses have a more established role in 
hacking into the miRNA pool of the host to promote its 
replication. Liver-specifi c miRNA122 has an extensive role 
in the regulation of lipid metabolism, hepatocarcinogensis 
and hepatitis C virus replication. MiRNA122 binds to the 5 
end of the hepatitis C virus genome, resulting in increased 
gene expression. In fact, there are two miRNA122 binding 
sites on the HCV genome and they carry out cooperative 
postion-dependant functions (Jopling et al. 2008). Liver 
miRNA122 has effects on hepatitis B virus replication but 
of a different manner than that of HCV. Overexpression 
studies of miRNA122 have shown inhibition of HBV 
viral replication and reduction in HBV viral load, while 
depletion has resulted in higher HBV replication (Qiu et 
al. 2010). Such modulation of HBV replication by miRNA 
can be a means of viral immune evasion to escape antigen 
presentation, or can be an effective strategy in limiting HBV 
replication.
It is still unclear, though, as to how viruses deal with 
potentially inhibitory effects of the large number of cellular 
miRNAs, prospective targets pf viral RNA genomes or 
mRNAs.
6. Epigenetic therapeutics: use of HDAC inhibitors as 
or in combination with anti-viral drugs
Chemical compounds that interfere with the epigenetic 
immune evasion strategies of pathogens can be used as 
drugs against infections caused by them. One such class of 
compounds are the HDAC inhibitors (HDACi). “Classical” 
HDACi acting on Zn2+-dependent HDACs (HDACs 1-11) 
include short-chain fatty acids, such as sodium butyrate and 
valproic acid (VPA); hydroxamic acids, such as trichostatin 
A (TSA) and suberoylanilide hydroxamic acid (SAHA); 
benzamides, such as MS275; and cyclic tetrapeptides such 
as trapoxin and depsipeptide (Bolden et al. 2006; Minucci 
and Pelicci 2006; Walkinshaw and Yang 2008; Mai and 
Altucci 2009). Inhibitors of Zn2+-dependent HDACs act 
by chelating or displacing the Zn2+ present in the catalytic 
site. Specifi city of such HDACi arise from interactions with 
the cap region that is adjacent to the catalytic site (Richon 
and O’Brien 2002; Bottomley et al. 2008; Schuetz et al. 
2008).
One of the major areas of research on HDACi as anti-
virals has been in the case of HIV. HIV infection today can 
be dramatically ameliorated by HAART. HAART acts by 
shutting down virus production. The success of HAART 
has hit a roadblock because of the low level of viral 
replication in infected cells and the prevalence of latency of 
HIV in resting CD4+ cells (Routy 2005). Most CD4+ cells 
are activated after HIV infection and undergo apoptosis. 
However, a small population of the activated cells return 
from an activate state to a resting one (Younes et al. 2003). 
HIV genomes integrated into such cells remain indefi nitely 
present as a reservoir capable of HIV replication (Siliciano 
et al. 2003). Valproic acid, an HDACi, has been shown to 
effectively induce HIV out of latency from resting cells 
by inhibiting the gene-silencing activity of HDAC2 and 
its CpG-island-binding complex containing MBD2. As a 
result, the acetylated histones free the promoter of the latent 
HIV genome while the demethylated CpG islands allow 
transcription factors to start gene transcription. This enables 
detection of HIV particles and their subsequent shutting 
down and clearing of by HAART. SAHA, another HDACi 
acting in a similar manner as valproic acid, is also capable 
of inducing latent viral infection out of HIV and is being 
considered as an effective and less-toxic alternative for the 
treatment of HIV patients (Edelstein et al. 2009).
7. Discussion and future perspectives
The co-evolution of viruses and hosts has resulted in 
many anti-viral mechanisms that shut down the replication 
machinery of the virus. For the same reason, different 
viruses have evolved devices to counter host innate immune 
responses. Most of the strategies employed are very complex, 
and they still elude the greatest efforts of the scientifi c 
community at unraveling them. The viral genome can be 
considered to be mutated half-brothers of the host genome, 
and this enables them to effi ciently utilize the host replication 
and transcriptional machinery for their propagation. The 
mechanisms of epigenetic control of gene expression 
continue to baffl e scholars. Yet, pathogens have intrinsically 
incorporated these machineries to propagate their species. 
Recent efforts have discovered the various interactions that 
pathogens have with the host on an epigenetic level, and 
it has been observed that such studies may provide novel 
and more effective attempts at drug discovery against such 
pathogens.
Small pox, caused by members of the family Poxviridae, 
has been eradicated through vaccination. Poliomyelitis, 
caused by Poliovirus, can be controlled by vaccination. 
However, it does not have any cure. A vast majority of 
viruses are constantly undergoing mutation and are evolving 
into newer and more-virulent strains. Development of 
vaccines against such pathogens is a complicated task, and 
anti-viral drugs a near impossibility. In these circumstances, 
scientists have discovered a common evolutionarily 
conserved mechanism of viral host immune evasion, and 
that is through the modulation of expression of host anti-
viral effector proteins through epigenetic silencing. Thus, 
the challenge today is in the discovery of unique inhibitors 
of epigenetic silencers such as HDACs and MBDs that can 
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assist activation of host immune reponse genes by interfering 
with the pathogenesis of viruses.
As explained above, viruses of the families Retroviridae 
(HIV and BLV), Polyomaviridae (SV40), Hepadnaviridae 
(HBV), Herpesviridae (EBV, HSV and VZV) and 
Papillomaviridae (HPV) show immune evasion tactics by 
epigenetic means. HCV and DNV of the Flaviviridae family 
also show epigenetic modulatory capabilities. The infl uenza 
A virus (IAV), a (–)ssRNA virus of the Orthomyxoviridae 
family, has been reported to cause apoptosis in host. During 
IAV infection, HDAC6, a multi-substrate cytoplasmic 
enzyme, has been shown to undergo cleavage by caspase 
3 (Husain and Harrod 2009). HDAC6 belongs to class 
IIb HDACs, and its suppression has been reported to be 
benefi cial for viral infection (Valenzuela-Fernández et al. 
2008). Many other viruses have the ability to disrupt the 
host’s innate immunity, although the epigenetic link still 
remains to be studied in most cases. (+)ssRNA viruses of the 
Flaviviridae family including the Japanese encephalitis virus 
(JEV) have the ability to suppress innate immune responses 
in a way that suggests putative epigenetic mechanisms. 
Studies involving administration of DNA vaccines (pE, a 
plasmid encoding the E-protein of JEV which enables anti-E 
Ab production) have shown strong suppression of humoral 
and cellular immune responses. T-helper cell response, 
which mediate major peripheral immune responses, have 
been shown to be effected (Chen et al. 2001). It is yet to be 
studied whether epigenetic mechanisms are involved in such 
inhibition of immunity.
There is still much ambiguity over the epigenetic 
mechanisms of viral immune evasion. It is a great challenge 
for future scientists to unravel the nuances of viral 
epigenetics. Most of the discovered mechanisms are still 
incomplete. The various types of histone modifi cations other 
than acetylations and methylations are yet to be well-studied. 
The roles of the various histone-modifying proteins and 
DNA methylation proteins are inconclusive to a large extent. 
HDACs themselves are a large class of proteins that have 
a wide range of unidentifi ed protein-modifying functions 
operating outside the nucleus. Immune genes are present in 
clusters in chromosomes. A study of the regulation of the 
immune gene clusters may lead to the development a much 
larger and complicated mechanism of epigenetic regulation. 
Studies on HIV and DNA viruses have been pioneering 
works in the fi eld of viral epigenetics. They has opened up a 
plethora of questions regarding viral immune evasion and a 
new chapter in the mechanism of host innate immunity.
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